General Information of Drug (ID: DMSP4JX)

Drug Name
Cetraxate Drug Info
Synonyms Neuer; NeuerCap; NeuerS; Cetraxate hydrochloride; DV-1006
Indication
Disease Entry ICD 11 Status REF
Peptic ulcer DA61 Approved [1]
Cross-matching ID
PubChem CID
2680
ChEBI ID
CHEBI:17340
CAS Number
CAS 34675-84-8
TTD Drug ID
DMSP4JX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bortezomib DMNO38U Leukemia Approved [3]
Ecallantide DMOF2C6 Retina venous occlusion 9B74.1 Approved [4]
LM-030 DMSJOE3 Congenital ichthyosiform erythroderma EC20.02 Phase 2 [5]
Benzoxazinone derivative 2 DM4FHTG N. A. N. A. Patented [6]
Benzyl amine derivative 1 DMOU84B N. A. N. A. Patented [6]
Benzyl amine derivative 2 DMFK7EL N. A. N. A. Patented [6]
Heteroaryl-carboxamide derivative 11 DM1CWU7 N. A. N. A. Patented [6]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Kallikrein-related peptidase (KLK) TT5L2VC NOUNIPROTAC Modulator [2]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48.
3 Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
4 Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.